U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C3H5O3.Ag.H2O
Molecular Weight 214.9535
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILVER LACTATE MONOHYDRATE

SMILES

O.[Ag+].CC(O)C([O-])=O

InChI

InChIKey=RKVLDPOOWODDMR-UHFFFAOYSA-M
InChI=1S/C3H6O3.Ag.H2O/c1-2(4)3(5)6;;/h2,4H,1H3,(H,5,6);;1H2/q;+1;/p-1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/monograph/silver-nitrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18245232

Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.

Originator

Orisheva, R.M.|Nechepurenko, Yu.V.|Sokolov, V.G.
16
Sources: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990https://www.ncbi.nlm.nih.gov/pubmed/20429870
Curator's Comment: The medical uses of silver date back to at least the time of Hippocrates

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
661
Substrate
661
Substrate
661
Substrate
661
Substrate
661
Substrate
661
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Advantage Arrest Silver Diamine Fluoride

Approved Use

Unknown
Primary
Approved
8583
Advantage Arrest Silver Diamine Fluoride

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Curative
Not Provided
511
Unknown

Approved Use

Unknown
Curative
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Not Provided
511
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Primary
Not Provided
511
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Palliative
Approved
8583
Unknown

Approved Use

Antiseptic Wound Cauterization
Primary
Approved
8583
Unknown

Approved Use

Prophylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth.
PubMed

PubMed

TitleDatePubMed
Topical antimicrobials for burn wound infections.
2010 Jun
Cleaning and decontamination efficacy of wiping cloths and silver dihydrogen citrate on food contact surfaces.
2012 Jul
UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent.
2016 Jan
An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care.
2016 Mar-Apr
Directional growth of Ag nanorod from polymeric silver cyanide: A potential substrate for concentration dependent SERS signal enhancement leading to melamine detection.
2017 Aug 5
The antifungal effects and mechanical properties of silver bromide/cationic polymer nano-composite-modified Poly-methyl methacrylate-based dental resin.
2017 May 8
Patents

Patents

04210711
16
04840956
16
06280923
16
06607872
16
07732486
16
08492554
16
20030220241
16
20060084679
16
20060270701
18
20110301181
16
20130072690
16
6989383
17
7553861
16
CN102923966
17
CN106167630
16
US1610391
16
US2249023
16
US2250390
16
US3639575A
16
US4391799A
16
US6180584
16

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Toxicity data
Topical as a 1:80 dilution (30 ppm ionic silver).
Route of Administration: Topical
In Vitro Use Guide
10 mkl volume of undiluted human norovirus 20% faecal suspension was mixed with 90 mkl of SDC (Silver Dihydrogen Citrate) for various contact times (15, 30, 60, 120, 300, 600 and 1800 s). At each sampling time point, 20 mkl of this solution was added to 180 mkl of 10% solution of Dey/Engley (D/E) neutralizing broth (Thermo Fisher Scientific, Waltham, MA). Samples were aliquoted and frozen at -80°C prior to nucleic acid extraction.
Name Type Language
SILVER LACTATE MONOHYDRATE [MI]
Preferred Name English
SILVER LACTATE MONOHYDRATE
MI  
Systematic Name English
SILVER, (2-(HYDROXY-.KAPPA.O)PROPANOATO-.KAPPA.O)-, HYDRATE (1:1)
Common Name English
Code System Code Type Description
CAS
19025-99-1
Created by admin on Mon Mar 31 23:04:39 GMT 2025 , Edited by admin on Mon Mar 31 23:04:39 GMT 2025
PRIMARY
PUBCHEM
22600159
Created by admin on Mon Mar 31 23:04:39 GMT 2025 , Edited by admin on Mon Mar 31 23:04:39 GMT 2025
PRIMARY
FDA UNII
67E6H10EYR
Created by admin on Mon Mar 31 23:04:39 GMT 2025 , Edited by admin on Mon Mar 31 23:04:39 GMT 2025
PRIMARY
MERCK INDEX
m9926
Created by admin on Mon Mar 31 23:04:39 GMT 2025 , Edited by admin on Mon Mar 31 23:04:39 GMT 2025
PRIMARY Merck Index
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966